Oregon Public Employees Retirement Fund purchased a new stake in shares of Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,832 shares of the medical research company’s stock, valued at approximately $2,260,000.

Other large investors also recently added to or reduced their stakes in the company. Ostrum Asset Management bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the first quarter valued at about $121,000. Eagle Boston Investment Management Inc. bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the first quarter valued at about $206,000. Raymond James Trust N.A. bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the second quarter valued at about $212,000. World Asset Management Inc bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the second quarter valued at about $213,000. Finally, Cigna Investments Inc. New bought a new stake in Bio-Rad Laboratories, Inc. Class A Common Stock during the first quarter valued at about $219,000. 63.19% of the stock is owned by institutional investors and hedge funds.

Several research firms have issued reports on BIO. Zacks Investment Research raised Bio-Rad Laboratories, Inc. Class A Common Stock from a “hold” rating to a “buy” rating and set a $334.00 price target for the company in a report on Monday, June 25th. Barclays began coverage on Bio-Rad Laboratories, Inc. Class A Common Stock in a report on Wednesday, September 5th. They set an “equal weight” rating and a $345.00 price target for the company. Finally, Jefferies Financial Group boosted their price target on Bio-Rad Laboratories, Inc. Class A Common Stock from $325.00 to $355.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $317.33.

Shares of Bio-Rad Laboratories, Inc. Class A Common Stock stock opened at $305.73 on Thursday. Bio-Rad Laboratories, Inc. Class A Common Stock has a 52 week low of $214.44 and a 52 week high of $345.15. The stock has a market capitalization of $9.20 billion, a PE ratio of 59.08, a price-to-earnings-growth ratio of 3.37 and a beta of 0.95. The company has a current ratio of 4.50, a quick ratio of 3.17 and a debt-to-equity ratio of 0.09.

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) last announced its quarterly earnings data on Tuesday, August 7th. The medical research company reported $1.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.37. Bio-Rad Laboratories, Inc. Class A Common Stock had a return on equity of 4.23% and a net margin of 44.77%. The business had revenue of $575.91 million for the quarter, compared to the consensus estimate of $551.05 million. equities research analysts anticipate that Bio-Rad Laboratories, Inc. Class A Common Stock will post 6.1 EPS for the current fiscal year.

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: Fundamental Analysis and Choosing Stocks

Institutional Ownership by Quarter for Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Class A Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. Class A Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.